Kombiglyze XR pills approved in Korea for treatment of type 2 diabetes in adults

Published: 2012-05-30 06:56:00

Updated: 2012-05-30 06:56:00

Bristol-Myers Squibb (BMS) Korea announced Sunday that the Korea Food and Drug Administration approved Kombiglyze XR tablets 2.5/1000mg for the treatment of type 2 diabetes in adults, following its approval of the same brand 5/500mg and 5/1000mg on April 12.

Co-developed by AstraZeneca, Kombiglyze XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.